摘要
目的 探讨大剂量依托泊苷(VP-16)联合重组人粒细胞集落刺激因子(G-CSF)方案对淋巴瘤患者自体外周血造血干细胞动员的效果及安全性。方法 回顾性分析2010年5月至2018年5月经自体外周血造血干细胞移植(APBSCT)治疗的60例淋巴瘤患者临床资料。结果 60例患者均良好耐受动员、采集过程,造血重建顺利,无一例移植相关死亡。VP-16+G-CSF组全部采集成功,首次采集成功率为73%(44/60),采集优良率为17%(10/60),且采集物中CD34+细胞计数高于化疗+G-CSF组。结论 大剂量VP-16联合G-CSF方案总体成功率高,不良反应可控,是恶性淋巴瘤患者动员采集安全有效的方案。
Objective To evaluate the efficacy and safety of high-dose etoposide(VP-16)combined with recombinant granulocyte colony stimulating factor(G-CSF)in the mobilization of autologous peripheral hematopoietic stem cells in patients with malignant lymphoma.Methods Clinical data of 60 patients with lymphoma treated with autologous peripheral hematopoietic stem cell transplantation(APBSCT)between May 2010 and May 2018 were retrospectively analyzed.Results All patients had good tolerance to the process of mobilization and blood collection,and all of them successfully completed hematopoietic reconstruction after transplantation.There was no any death related to transplantation.All the samples were successfully collected in the VP-16+G-CSF group.The success rate of the first collection was 73%(44/60),the excellent rate was 17%(10/60),and the CD34+cell count in the samples was higher than that in the chemotherapy+G-CSF group.Conclusion High-dose VP-16 with recombinant G-CSF for mobilization of autologous peripheral blood stem cell is with higher success rate and controllable adverse effects,and therefore represents an effective and safe mobilizing regimen for patients with malignant lymphoma.
作者
赵瑾
苏丽萍
关涛
王江涛
刘小兰
Zhao Jin;Su Liping;Guan Tao;Wang Jiangtao;Liu Xiaolan(Department of Hematology,Shanxi Cancer Hospital of Shanxi Medical University,Taiyuan 030013,China)
出处
《中国药物与临床》
CAS
2020年第6期890-892,共3页
Chinese Remedies & Clinics
基金
山西省卫生计生委科研课题(2017079)。
关键词
淋巴瘤
造血干细胞
依托泊苷
Lymphoma
Hematopoietic stem cells
Etoposide
